Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome DOI Creative Commons
Richard J. MacIsaac

Future Cardiology, Год журнала: 2025, Номер unknown, С. 1 - 21

Опубликована: Июнь 3, 2025

Recent trials underscore the cardiovascular (CV), renal, and metabolic benefits of semaglutide in individuals with without type 2 diabetes (T2D). In T2D, enhances glycemic control, reduces major adverse CV events (MACE), slows chronic kidney disease (CKD) progression. The SUSTAIN-6 trial demonstrated a 26% MACE reduction (HR 0.74; 95% CI: 0.58-0.95; p = 0.02) high CV-risk patients T2D using (0.5 or 1.0 mg weekly). Similarly, FLOW showed 24% 0.76; 0.66-0.88; 0.002) weekly CKD. Beyond SELECT highlighted semaglutide's efficacy reducing by 20% 0.80; 0.72-0.90; < 0.001) slowing function loss overweight obese preexisting 2.4 weekly. Additionally, alleviates heart failure symptoms hospitalizations regardless status. These findings role improving kidney, CV, survival outcomes among high-risk patients. This review highlights cardio-kidney-metabolic to inform cardiologists about its potential enhance patient care.

Язык: Английский

Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology DOI Creative Commons
Melania Gaggini, Laura Sabatino,

Adrian Florentin Suman

и другие.

Cells, Год журнала: 2025, Номер 14(5), С. 387 - 387

Опубликована: Март 6, 2025

In recent years, new drugs for the treatment of type 2 diabetes (T2D) have been proposed, including glucagon-like peptide 1 (GLP-1) agonists or sodium–glucose cotransporter (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors. Over time, some these agents (in particular, GLP-1 SGLT2 inhibitors), which were initially developed their glucose-lowering actions, demonstrated significant beneficial pleiotropic effects, thus expanding potential therapeutic applications. This review aims to discuss mechanisms, GLP-1, DPP-4, SGLT2, with a particular focus on cardiorenal benefits beyond glycemic control.

Язык: Английский

Процитировано

1

Anti-consumption agents: Tirzepatide and semaglutide for treating obesity-related diseases and addictions, and improving life expectancy DOI Creative Commons
James H. O’Keefe,

William Grant Franco,

Evan L. O’Keefe

и другие.

Progress in Cardiovascular Diseases, Год журнала: 2024, Номер unknown

Опубликована: Дек. 1, 2024

Язык: Английский

Процитировано

4

GLP‐1 Agonists as Potential Neuromodulators in Development of Parkinson's Disease: A Nationwide Cohort Study DOI Creative Commons
Mads Gamborg, Mia Klinten Grand,

Jasmin Arvedsen

и другие.

European Journal of Neurology, Год журнала: 2025, Номер 32(2)

Опубликована: Фев. 1, 2025

Parkinson's disease is a progressive neurodegenerative disorder with no cure. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may have neuroprotective effects. However, long-term real-world studies are needed to clarify their potential impact on disease. This nationwide cohort study included 33,462 patients (16,731 GLP-1RA initiators and 16,731 propensity score-matched dipeptidyl peptidase-4 inhibitor [DPP-4i] initiators) from 2007 2018, followed until 2022. Eligible participants were ≥ 50 years, had prior cancer or disease, residents in Denmark for at least 10 years. Patients diagnosis, death, emigration, treatment discontinuation (no additional prescription within 180 days), switch the other drug, end of follow-up. Additional analyses comparisons insulin, competing risk main analysis disregarding adherence. During follow-up, 192 developed including 93 during sustained treatment. After users lower hazard ratio (HR 0.57 (95% CI 0.37;0.85)) absolute difference (-0.24 -0.63 0.15)) compared DPP-4i users. Similar trends found when using insulin as comparator. A significant survival advantage was among (particularly comparing insulin). When not accounting adherence, results statistically significant. Results suggestive effect GLP-1RAs against Further assess biomarkers progression, evaluate safety dosing, effects combined treatments diseases.

Язык: Английский

Процитировано

0

Glucagon-like-peptide-1-Rezeptoragonisten: eine neue pharmakologische Behandlungsoption für psychiatrische Erkrankungen? DOI Creative Commons
Hubertus Himmerich

Der Nervenarzt, Год журнала: 2025, Номер unknown

Опубликована: Март 5, 2025

Albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, orforglipron and semaglutide are glucagon-like peptide‑1 (GLP-1) receptor agonists. Tirzepatide targets not only GLP‑1 but also glucose-dependent insulinotropic peptide (GIP) receptors retatrutide is a triple GLP‑1, GIP glucagon agonist. The agonists increase insulin release suppress release. They slow down the emptying of stomach thus prevent blood sugar spikes. reduce appetite food intake. In brain lead to better glycemic control they appear have anti-inflammatory neuroprotective effects. It has been reported that oxidative stress apoptosis, lower risk ischemia promote neurogenesis. can influence dopaminergic signal transduction in nucleus accumbens. Therefore, could modify effect cocaine, alcohol nicotine. Preliminary investigations provide indications therapeutic benefits for people with dementia, eating disorders, psychopharmacologically induced weight gain, depression, anxiety substance use disorders. Typical accompanying adverse reactions gastrointestinal side effects, such as nausea, vomiting, diarrhea, eructation gastroesophageal reflux. More severe effects include pancreatitis, allergic reactions, renal function disorders possibly an increased thyroid cancer.

Язык: Английский

Процитировано

0

Semaglutide to remodel mitochondrial dynamics and mitophagy balance for vascular dementia therapy DOI Creative Commons
Xiaoyan Yang,

Peng Feng,

Hongxu Zhu

и другие.

View, Год журнала: 2025, Номер unknown

Опубликована: Апрель 7, 2025

Abstract Vascular dementia (VaD) is a syndrome of cognitive dysfunction caused by cerebrovascular damage. At present, VaD mainly prevented controlling vascular risk factors clinically, while there has been limited progress in therapies directly targeting its pathological mechanism. Mitochondrial plays key role the pathogenesis VaD, but are no drugs to improve regulating mitochondrial function clinical practice. In this study, semaglutide was used as an intervention therapy and results showed that could regulate balance dynamics mitophagy activating phosphatidylinositol 3‐kinase/protein kinase B signaling pathway, adjust phenotype glial cells from proinflammatory states anti‐inflammatory states, dysfunction. This study identifies therapeutic way linking hippocampal neuronal protection, reduction pathology, restoration function, with important implications for treatment VaD.

Язык: Английский

Процитировано

0

Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders DOI
Riccardo De Giorgi, Ana Ghenciulescu,

Courtney Yotter

и другие.

Journal of Neurology Neurosurgery & Psychiatry, Год журнала: 2025, Номер unknown, С. jnnp - 335593

Опубликована: Апрель 10, 2025

Disease-modifying treatments for major neurocognitive disorders, including Alzheimer’s disease, Parkinson’s disease and other cognitive deficits, are among the main unmet needs in modern medicine. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently licensed treatment of type 2 diabetes mellitus obesity, offer a novel, multilayered mechanism intervention neurodegeneration through intermediate, aetiology-agnostic pathways, likely involving metabolic, inflammatory several relevant neurobiological processes. In vitro animal studies have revealed promising signals neuroprotection, with preliminary supportive evidence emerging from recent pharmacoepidemiological investigations clinical trials. this article, we comprehensively review that investigate impact GLP-1RAs on various aetiologies impairment dementia syndromes. Focusing human studies, highlight how brain energy homeostasis, neurogenesis, synaptic functioning, neuroinflammation cellular stress responses, pathological protein aggregates, proteostasis, cerebrovascular system blood-brain barrier dynamics may underlie GLP-1RA putative neuroprotective effects. We then report appraise observational investigations, trials pooled analyses. Finally, discuss current challenges perspectives ahead research implementation care people their individual penetrance potential, need response biomarkers stage-based indications, possible non-specific effects health, profile terms adverse events unwanted effects, lack long-term data efficacy safety, issues surrounding cost availability treatment.

Язык: Английский

Процитировано

0

The Expanding Role of GLP-1 Receptor Agonists: Advancing Clinical Outcomes in Metabolic and Mental Health DOI Creative Commons

Mohamad Al Qassab,

M.A. Mneimneh,

Ahmad Jradi

и другие.

Current Issues in Molecular Biology, Год журнала: 2025, Номер 47(4), С. 285 - 285

Опубликована: Апрель 17, 2025

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have emerged as a promising therapeutic option beyond their established role in managing type 2 diabetes mellitus (T2DM) and obesity. Recent research has highlighted beneficial effects on liver, kidney, cardiovascular health, mediated by both direct indirect mechanisms. In the GLP-1 RAs contribute to improvement of metabolic dysfunction-associated steatotic liver disease (MASLD) reducing hepatic fat accumulation, inflammation, oxidative stress. Additionally, they enhance insulin sensitivity lipid metabolism. Similarly, diabetic kidney (DKD), exhibit renoprotective properties mitigating stress, glomerular hypertension. Furthermore, promote natriuresis stabilize renal function. Moreover, present significant benefits, including improved myocardial function, reduced atherosclerosis progression, enhanced endothelial decreased major adverse events (MACEs). emerging evidence suggests may exert substantial neuropsychiatric reductions depressive symptoms, anxiety, substance use behaviors, lowering risk Alzheimer’s disease, Parkinson’s other dementias likely modulation neurotransmitter systems neuroinflammation. Genetic polymorphisms GLP1R gene also impact response, highlighting importance personalized medicine optimizing RA efficacy. This review synthesizes preclinical clinical supporting multifaceted across multiple organ systems, potential glycemic control. As advances, further exploration mechanisms action long-term outcomes, safety effectiveness diverse patient populations will be essential treating conditions.

Язык: Английский

Процитировано

0

The Critical Role of GLP-1 Signaling Pathways in the Pathology of Parkinson's Disease and Diabetes DOI
Jinhao Chen, Xiang Dong,

Yi-Chen Lin

и другие.

Pathology - Research and Practice, Год журнала: 2025, Номер unknown, С. 155985 - 155985

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0

Linking Metabolic Syndrome to Neurodegeneration Mechanisms and Potential Treatments DOI

Amina Džidić-Krivić,

Almir Fajkić,

Esma Karahmet Farhat

и другие.

Molecular Neurobiology, Год журнала: 2025, Номер unknown

Опубликована: Апрель 24, 2025

Язык: Английский

Процитировано

0

Exploring the Impact of Diabetes Mellitus on Clinical Outcomes in Patients Following Severe Traumatic Brain Injury Using the TriNetX Database DOI Creative Commons

Kamal Shaik,

S. Rasmussen,

Rudy J. Rahme

и другие.

Surgeries, Год журнала: 2025, Номер 6(2), С. 38 - 38

Опубликована: Апрель 30, 2025

Introduction: Traumatic brain injury (TBI) involves a diverse group of head blunt and/or penetrating injuries and is leading cause death in the U.S., accounting for one-third all injury-related deaths. A post-injury hyperglycemic state may commonly impact TBI prognosis strongly correlate with severity. Diabetes mellitus (DM) also be source concomitant hyperglycemia that can worsen prognosis, previous literature suggesting DM could an independent predictor poor outcome mortality after TBI. Methods: Using multi-center, national TriNetX database, we performed propensity score-matched analysis severe patients without (NDM) from 2014 to 2024. We examined risk complications, including sepsis, cerebral infarction, pulmonary embolism. sub-group comparing complications between either insulin-dependent or insulin-independent forms DM. Results: total 26,019 were included (4604 vs. 21,415 NDM). After score matching, had significantly lower (RR: 0.815; 95% CI: 0.771–0.861; p < 0.05) ventilator dependency 0.902; 0.844–0.963; compared NDM patients. However, higher infarctions, seizures, pneumonia, sepsis (p 0.05). Sub-group found no significant difference Conclusion: Our results suggest secondary plays complicated role outcomes Unexpectedly, identified both increased decreased These reflect current challenges surrounding pre-existing patients’ outcomes, diabetic medications on patient changing aggressive glucose management critical care

Язык: Английский

Процитировано

0